3i final close on Europes largest mid-market buyout fund
3i, a leading global private equity and venture capital company, today announces that its pan-European Buyout business (‘3i Buyouts’) has successfully completed the close of its latest buyout fund, ‘Eurofund V’.
The amount committed is €5bn, well beyond the initial intended target of €3.5bn, and is now the largest fund dedicated to the mid-market in Europe.
The fund includes investment from a high quality and well-diversified group of 62 LPs from all over the world. Eurofund V will target around 50 investments across Europe over the next four years, primarily in Europe, but with some scope to invest outside of Europe, benefiting from 3i’s expanding network throughout Asia.
3i Buyouts is the European mid-market leader, with c€8bn in funds under management. The business invests in mid-market transactions with a typical enterprise value of up to €1bn in a wide range of sectors, with a focus on media, healthcare, business services and consumer. 3i Buyout’s competitive edge comes from its pan-European network and global sector insight, access to operating capabilities and delivering unique market access for deal flow and value creation.
Paul Waller, a Managing Partner at 3i, commented: “We are thankful to have received such strong support from existing investors in 3i funds. We are equally delighted to welcome many new investors to the fund, a large proportion of those coming from North America and the Middle East”.
3i is a world leader in private equity and venture capital. We focus on buyouts, growth capital and venture capital and invest across Europe, in the United States and Asia. Our competitive advantage comes from our international network and the strength and breadth of our relationships in business. These underpin the value that we deliver to our portfolio and to our shareholders. www.3i.com
The latest fund follows another successful year for 3i Buyouts. Significant realisations across Europe include the sale of: German generic prescription drugs distributor, betapharm; own-label Dutch fruit juice business, Refresco; Swedish clothing, home and accessories retailer Gant; UK environmental due diligence firm ERM; International foreign exchange specialist Travelex; and pan-European business Yellow Brick Road.